Infectious Diseases Week 2020
October 22-25, 2020 | Virtual
Czarnogorski M, et al. Qualitative Findings from a Hybrid III Implementation-Effectiveness Study to Explore Perspectives of Health-care Staff on Early Implementation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Injectable HIV treatment in the US (CUSTOMIZE). Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Poster 1037.
Czarnogorski M, et al. Summary of COVID-Related Impact on the Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Dosing Across the Six Largest Phase III and IIIb/IV Ongoing Clinical Trials. Presented at IDWeek 2020, October 22-25, 2020, Virtual Event. Oral Presentation.
Saturday, October 24, 2020 11:00am — 11:10am EDT Location: Channel 1
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
Connect With Our Medical Experts
Request a Scientific Discussion
Submit a request for additional information from a ViiV Medical Expert.
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch